Frias Boligan, KayluzKayluzFrias BoliganOechtering, JohannaJohannaOechteringKeller, Christian WChristian WKellerPeschke, BenjaminBenjaminPeschkeRieben, RobertRobertRieben0000-0003-4179-8891Bovin, NicolaiNicolaiBovinKappos, LudwigLudwigKapposCummings, Richard DRichard DCummingsKuhle, JensJensKuhlevon Gunten, StephanStephanvon GuntenLünemann, Jan DJan DLünemann2024-09-022024-09-022020-03https://boris-portal.unibe.ch/handle/20.500.12422/33936OBJECTIVE To explore the repertoire of glycan-specific immunoglobulin G (IgG) antibodies in treatment-naive patients with relapsing-remitting multiple sclerosis (RRMS). METHODS A systems-level approach combined with glycan array technologies was used to determine specificities and binding reactivities of glycan-specific IgGs in treatment-naive patients with RRMS compared with patients with noninflammatory and other inflammatory neurologic diseases. RESULTS We identified a unique signature of glycan-binding IgG in MS with high reactivities to the dietary xenoglycan N-glycolylneuraminic acid (Neu5Gc) and the self-glycan N-acetylneuraminic acid (Neu5Ac). Increased reactivities of serum IgG toward Neu5Gc and Neu5Ac were additionally observed in an independent, treatment-naive cohort of patients with RRMS. CONCLUSION Patients with MS show increased IgG reactivities to structurally related xenogeneic and human neuraminic acids. The discovery of these glycan-specific epitopes as immune targets and potential biomarkers in MS merits further investigation.en600 - Technology::610 - Medicine & healtharticle10.7892/boris.1402093201484910.1212/NXI.0000000000000676